1063712-62-8

Basic information

• Product Name: 1-benzyloxy-4-bromo-2-(3,3-dimethyl-1-butynyl)benzene
• Synonyms: 1-benzyloxy-4-bromo-2-(3,3-dimethyl-1-butynyl)benzene
• CAS NO: 1063712-62-8
• Molecular Weight: 343.263
• Mol File: 1063712-62-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-benzyloxy-4-bromo-2-(3,3-dimethyl-1-butynyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyloxy-4-bromo-2-(3,3-dimethyl-1-butynyl)benzene(1063712-62-8)
• EPA Substance Registry System: 1-benzyloxy-4-bromo-2-(3,3-dimethyl-1-butynyl)benzene(1063712-62-8)

Safety Data

• Hazardous Substances Data: 1063712-62-8(Hazardous Substances Data)

Upstream product

• 1063712-60-6 4-benzyloxy-3-(3,3-dimethyl-1-butynyl)aniline 
• 612833-66-6 1-(benzyloxy)-4-bromo-2-iodobenzene 
• 917-92-0 3,3-Dimethylbut-1-yne 

Downstream Products

• 1063712-64-0 4-benzyloxy-3-(3,3-dimethyl-1-butynyl)phenylboronic acid 

Relevant articles and documents

Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: Effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of Src homology 2 domain-containing protein tyrosine phosphatase-2 activity

(E)-4-[3-(1-Adamantyl)-4′-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell-cycle arrest and apoptosis of leukemia and cancer cells. Studies demonstrated that 3-Cl-AHPC bound to the atypical orphan nuclear receptor small heterodimer partner (SHP). Although missing a DNA-binding domain, SHP heterodimerizes with the ligand-binding domains of other nuclear receptors to repress their abilities to induce or inhibit gene expression. 3-Cl-AHPC analogues having the 1-adamantyl and phenolic hydroxyl pharmacophoric elements replaced with isosteric groups were designed, synthesized, and evaluated for their inhibition of proliferation and induction of human cancer cell apoptosis. Structure-anticancer activity relationship studies indicated the importance of both groups to apoptotic activity. Docking of 3-Cl-AHPC and its analogues to an SHP computational model that was based on the crystal structure of ultraspiracle complexed with 1-stearoyl-2-palmitoylglycero-3-phosphoethanolamine suggested why these 3-Cl-AHPC groups could influence SHP activity. Inhibitory activity against Src homology 2 domain-containing protein tyrosine phosphatase 2 (Shp-2) was also assessed. The most active Shp-2 inhibitor was found to be the 3′-(3,3-dimethylbutynyl) analogue of 3-Cl-AHPC.